NI Research provides specialized publications for the biopharmaceutical industry, venture capital specialists, institutional and individual investors
NI Research is pleased to announce our newest publications
NI Research Special Report: Alzheimer’s 2008
NI Research is pleased to announce the release of Alzheimer’s 2008, our special report on the state of the race to develop therapeutics for the treatment of Alzheimer’s. This publication provides an overview of the pathophysiological models and therapeutic avenues being pursued, while discussing program prospects with a degree of specificity and frankness not to be found in other publications in this area. Alzheimer’s 2008 also includes a database of Alzheimer’s development programs, and discusses the best Alzheimer’s partnering candidates. Alzheimer’s 2008 builds upon the Alzheimer’s coverage provided by NI Research’s monthly publication, NeuroInvestment, revised and updated it so that it is absolutely current at the time of release.
Alzheimer’s 2008 has been designed to be the most concise and forthright overview of Alzheimer’s therapeutics-in-development available today. It has also been priced at a level that makes it affordable for companies and institutions of all sizes.
27 pages 2 Tables US$595
(Subscribers to NeuroInvestment can purchase Alzheimer’s 2008 for $395)Private CNS Company Database 2007-8
In 2003, NI Research produced the first-ever comprehensive report on the Private CNS Therapeutics industry. Up to that point, there had been no authoritative database available to meet the needs of Business Development and financial professionals evaluating strategic options for inlicensing, outlicensing, M&A, collaboration, and financing. It received an enthusiastic response from dozens of large, mid-size, and small pharma and biotech companies. Fully revised and updated each year, this database covers the privately-held companies in North America, Europe, and Oceania that are primarily devoted to the development of novel therapeutics for neurological and psychiatric disorders.
Private CNS Company Database 2007-8 improves upon its predecessors. It provides detailed summaries regarding private companies whose primary focus is in the area of CNS therapeutics. Information regarding their clinical/preclinical activity, scientific platforms, contact information, alliances, financing, and prospects are combined in one easily accessible resource. It also provides information regarding VC activity in the private CNS area and the performance of private CNS firms in terms of advancing their programs.
This edition also includes our first-ever ranking of the venture capital firms most frequently involved with CNS companies. The ranking is a quantified assessment of the quality of each VC firm's CNS portfolio from 2003-7.
137 pages
99 Companies
US$3300
Download sample entry from PCNS 2005
CNS 2007: Disorders/Therapeutics
CNS 2007-8: Disorders/Therapeutics represents a new era in information tailored for Pharma Business Development. Designed at the request of Business Development professionals, CNS 2007 combines in a single pdf volume NI’s renowned reviews of development programs organized by clinical disorder, all fully revised and updated as of May 2007. It provides a ‘one-stop’ overview of all major psychiatric and neurological disorders, assessing current mechanistic hypotheses, the R&D being devoted to each, and program prospects. It is ideal for teams evaluating strategic opportunities for inlicensing, outlicensing, M&A, collaboration, and financing. It is produced in pdf form for easy searchability. The 2007 edition includes full reviews of the following disorders, as well as numerous summary tables of development programs for each disorder:
ADHD
Alertness/EDS
Alzheimer’s
ALS
Anxiety
Depression
Epilepsy
Huntington’s
Insomnia Memory Disorders
Migraine
MS
Neuropathic Pain
Nociceptive Pain
Parkinson’s
Schizophrenia
Spinal Cord Injury
Spinal Muscular Atrophy
Stroke Traumatic Brain Injury300+ pages
US$5000 California-based companies must pay 7.75% state sales tax.
NeuroInvestment
This monthly industry review has been published by NI Research since 1995. It surveys the range of next-generation drug and cell therapies being developed for neurological and psychiatric disorders; the companies pursuing them; and the regulatory and financial institutions that have so much impact behind the scenes. For background and commentary, visit the NeuroInvestment website at www.neuroinvestment.com. Online orders can be placed on the Order page of this site.
Click here to download the October 2006 sample issue of NeuroInvestment